Introduction
Peripheral interface technologies have evolved over two centuries from Luigi Galvani's muscle twitch experiments in frogs (Galvani, 1791) to more refined techniques for both monitoring and controlling peripheral nerve activity. In addition to facilitating a greater understanding of neurological function, interfaces to the peripheral nervous system (PNS) have enabled new capabilities for multiple applications. In the past five years, the Defense Advanced Research Projects Agency's (DARPA) Biological Technologies Office has invested in peripheral nerve interfaces aimed at three application spaces: prosthetics (to restore sensorimotor function), electrical prescriptions (to diagnose, monitor, and treat disease), and neuroplasticity (to improve learning). Despite the separate therapeutic and performance objectives of these applications, technology developers face shared challenges in interfacing with peripheral nerves. These include optimizing the form factor, specificity, resolution, efficacy, and longevity of the final system, while keeping in mind the differences in risk-benefit tolerance for each application. In this commentary, we discuss design considerations for each type of peripheral interface system. We also comment on the potential ethical issues associated with the development of these new approaches.
algorithms to support neural interface performance for at least 12 months. Other goals included describing a credible trajectory for the technology to reach a lifetime of 70 years (DARPA, 2011) . In addition to animal demonstrations, some teams also translated their developed systems to human amputees to both decode motor signals and provide sensory feedback via neural stimulation.
In part due to efforts funded under RPI, the neural interface field has progressed to the point where neuroelectronic interfaces are less niche and are gaining wider adoption in an ever increasing commercial market (Prochazka, 2017) . Alternative classes of interfaces, such as those employing optics or acoustics, have also gained traction and continue to receive agency funding. Thanks to its focus on interface reliability, RPI also set the stage for the development of peripheral interfaces geared toward specific applications, which became the focus of three separate DARPA programs, described here.
Building on the advances enabled by RE-NET, the Hand Proprioception and Touch Interface (HAPTIX) program was launched in 2014 and aims to develop a fully-implantable bidirectional neuroprosthetic system for amputees. While the primary focus is on the hand, the HAPTIX portfolio includes investment in technology for integration in both upper and lower limb amputation. The final system is intended to be agnostic to the external prosthetic limb and consists of implantable electrodes and devices for recording residual motor signals and stimulating the peripheral nerve. HAPTIX also includes algorithm development. Motor "decoders" translate descending neural activity from residual muscles and/or nerves into motor commands for the prosthesis. At the same time, when the prosthesis comes into contact with objects, sensory "encoders" provide stimulation patterns to the nerve to produce location-specific cutaneous and/or proprioceptive feedback. Final HAPTIX goals include an extended take-home trial of the fully implantable technology in transradial amputees, who will use the system in conjunction with a sensorized six-degree of freedom prosthesis called the Life Under Kinetic Evolution, or "LUKE", arm (DEKA Research and Development Corporation, Manchester, New Hampshire). The LUKE arm was developed under the DARPA Revolutionizing Prosthetics program and was outfitted with position and contact sensors for HAPTIX (George et al., 2019) .
The Electrical Prescriptions (ElectRx) program, launched in 2015, intends to demonstrate that peripheral neuromodulation can provide non-pharmacological treatments for medical conditions such as pain, rheumatoid arthritis, joint inflammation, post-traumatic stress disorder (PTSD), irritable bowel disease (IBD), and metabolic disorders such as diabetes. Ideally, a final system would track internal biological markers that classify a disease state. Markers detected at a specific threshold would automatically trigger delivery of stimulation to a peripheral nerve to regulate the signals and bring the body or mind back to a nondisease state. To understand the necessary signals for control of the directed interfaces, ElectRx has created technologies to both identify and continuously monitor relevant biomarkers. Discovering which biomarkers denote disease state can provide objective feedback on efficacy of the intervention while eventually serving as the sensing component of an autonomous, closed-loop treatment system. With respect to nerve stimulation, while some ElectRx teams are focusing on invasive technologies, others are working toward noninvasive interfaces that may provide cell-type specificity (e.g. pain or excitatory/inhibitory cells) and minimize the side effects associated with conventional neural interfaces and pharmacological interventions.
The Targeted Neuroplasticity Training (TNT) program began in 2017 and seeks to improve learning by pairing peripheral nerve stimulation with task training. The TNT approach is based on the hypothesis that peripheral nerve stimulation can induce changes in synaptic plasticity through central neuromodulator release when paired temporally with sensorimotor or cognitive training tasks. This may lead to improved acquisition and performance of motor skills, sensory perception, and cognitive function. By exploring various parameters of peripheral nerve stimulation via existing and new devices, TNT aims to define neurobiological mechanisms of the resulting effects on plasticity, and how these mechanisms may lead to improvements in learning and performance. The ultimate goal of the program is to develop noninvasive nerve stimulation approaches (e.g. cutaneous surface electrodes, ear bud electrodes) that will be applicable for use by healthy individuals in DoD-relevant application spaces such as foreign language acquisition, target discrimination, intelligence analysis, and marksmanship. If TNT demonstrates outcomes that are robust, reliable, and beneficial, this technology may subsequently be applicable to learning a variety of complex skills.
Current system design and future considerations
Although HAPTIX, ElectRx, and TNT are developing new approaches and technologies to interface with the PNS in general, each one is ultimately focused on developing a system tailored for a specific application. As such, the tradeoffs between form factor, spatiotemporal resolution, and longevity are weighted differently and vary across the three applications. Moreover, the quantitative metrics used to evaluate efficacy may also vary between each use case. Current system design for the three application spaces, along with considerations for future technology development, is described below.
Form factor
Form factor considerations for peripheral nerve interfaces include both the form of the external devices as well as that of the implantable hardware. With respect to the external hardware, a major goal is to design a system that can be field-deployable or suitable for home-use, rather than one that is limited to a lab or restricted clinical setting. Progress toward this goal includes developing a system that relies on secure, high-bandwidth wireless communication rather than percutaneous leads, which are susceptible to infection and breakage (Barrese et al., 2013) . Improvements in implanted batteries or external powering/recharging, or even the ability to harness energy from the host, also foster broader adoption by minimizing the need for battery swapouts and bulky hardware.
The form factor of a technology may also impact the system's riskbenefit ratio to the end user. For example, hardware design for implantable devices affects the surgical approach, and the rate of complications ranges from ∼20-40%, depending on the target nerve, type of interface, and clinical application (Farinetti et al., 2014; Kemler et al., 2000; Kumar et al., 2006) . Hardware issues, such as lead fracture or disconnect, lead migration, or failure of the pulse generator, occur 24-50 % of the time (Kumar et al., 2006; Turner et al., 1995) . These relatively high percentages underscore the current risk of the technology and highlight the need for more robust systems. Although these risks may be worth the therapeutic benefits for prosthetics and for some aspects of bioelectronic medicine, implantable electrical interfaces may not be appropriate for all clinical needs or for application spaces involving healthy individuals. To minimize surgical risk, DARPA has funded alternative strategies for noninvasively stimulating nerves, such as transcutaneous electrical stimulation and focused ultrasound (FUS). The agency has also funded genetic methods (e.g., optogenetics, sonogenetics) to nonsurgically target subpopulations of neuronal cells. Initial data from these technologies seem promising but require further investigation into the biological mechanisms and stimulus parameter space to fully understand their potential benefits and limitations.
The HAPTIX program accepts the risk-benefit trade-off between implanted electrodes and advanced motor control and sensory feedback, and addresses other form factor considerations through its program goals. The final HAPTIX system should not include any percutaneous leads, and implanted components must communicate wirelessly to a wearable processor. Future goals for the prosthetics application space in general may include reducing the size and weight of external components and minimizing the frequency of battery changes, as these factors may deter prosthetic users from consistently using the system (Resnik et al., 2012) . While the HAPTIX-specific technology is agnostic to the prosthetic limb itself, ideally the prosthesis should also be relatively lightweight and free of additional external accessories.
ElectRx technologies vary in form factor depending on the final medical application, and include both commercially available noninvasive designs and new types of implantable devices (e.g., Payne et al., 2019; Sivaji et al., 2019) . The level of invasiveness of the final technology will ultimately depend on the acceptable risk-benefit ratio associated with each specific disease, yet the goal is to provide clinical demonstrations of noninvasive systems that can be used at home or in a bedside clinical setting. Other future form factor goals, such as size and battery life, are similar to those of HAPTIX, and also include designing the devices so that they target only the end organ of interestrequiring placement of the interface in locations that target specific nerve branches or fascicles. Form factors that facilitate repeatable noninvasive device placement by the end user will also be important for external solutions to ensure repeatability and precision.
The TNT program relies primarily on commercial off-the-shelf noninvasive technology for its human studies. However, future technology development may improve the form factor of devices tailored for healthy humans in the context of training applications. Ultimately, developers must consider two major aspects when designing such a system: 1) ergonomics and 2) integration with training paradigms. With respect to integration with current training paradigms, it is important to consider that form factor may vary depending on whether peripheral nerve stimulation is applied prior to or during training. Ecological conditions also become important here. For example, device requirements for a student learning a foreign language in a classroom setting are vastly different from those for an active sensorimotor task, such as marksmanship training. In general, the ideal device would need to be portable, require minimal training for repeatable use, have protections against misuse, and deliver reliable stimulation at the appropriate parameters deemed effective for the given application.
Across both medical and non-medical applications, user experience will be a critical factor in the development and refinement of peripheral nerve interface devices. Data and results from human studies and clinical trials will be important to shape the next generation of system designs to ensure that they can be easily used in the appropriate setting for the intended applicationat home, in point of care facilities, or elsewhere. In the end, efficacy and usability may ultimately inform implementation.
Resolution and specificity
Ongoing efforts to advance new capabilities for interfacing with nerves focus on improving the spatiotemporal resolution for both measuring and regulating neural activity. Importantly, both physical design and stimulation protocols, such as current steering, may be used to improve resolution. Recent investment in peripheral interfaces has focused on pushing the envelope on spatiotemporal resolution by investing in new designs, materials, and protocols depending on the desired application, described below.
Real-time prosthetics require the ability to provide sensory feedback with high temporal (milliseconds) and spatial (fascicle-level or better) resolution. To date, the field of sensory prosthetics has conducted human clinical demonstrations of spinal cord stimulation (Chandrasekaran et al., 2019) , penetrating (e.g., Davis et al., 2016; Jung et al., 2018; Overstreet et al., 2019; Raspopovic et al., 2014) and non-penetrating (e.g., Graczyk et al., 2019; Charkhkar et al., 2018) nerve electrode-based systems that provide high temporal resolution, but that vary with respect to spatial selectivity. Exact spatial resolution requirements are difficult to quantify and are often described with respect to functional outcomes, such as the size of the evoked sensory percepts or muscle activation (see Rijnbeek et al., 2018 ; Ghafoor et al., 2017 for reviews). While current electrical designs do not achieve clear cell-type specificity, different electrode styles are able to produce both cutaneous and proprioceptive percepts. Future research is needed to understand how to better recreate more nuanced modalities of sensation, such as texture, which may require improvements in cell-type specificity and/or the ability to modulate the activity of specific neural ensembles. These types of improvements in the resolution of the neural interface will also drive the design requirements of the prosthetic device. As the interfaces begin to provide smaller and more advanced percepts that approximate the sophistication of natural hand, prosthetic limbs will in turn require new integrated sensor designs. These novel sensors will need to decrease in size to facilitate the ability to discern a number of pinpointed haptic sensations.
With respect to the bioelectronic medicine, temporal resolution requirements are a primary focus and may vary depending on the disease. Unlike real-time systems for prosthetics, stimulation for treatment of disease can presumably be addressed on a slower time scale based on the rate of disease progression and associated biomarkers of disease state. However, biomarker measurements to track efficacy of treatment may have more precise temporal requirements in order to indicate the immediate nervous system response to stimulation (see Evaluation of Efficacy section). For spatial resolution, requirements should balance the needs of specific disease treatment with minimizing off-target effects. Subfascicular or cell-subtype specificity, in particular, may be important for certain diseases such as chronic pain, for which the device should specifically target pain fibers rather than general afferent or efferent fibers. The use of genetic approaches, such as optogenetics (Iyer et al., 2014) , enable cell-type specificity with the added benefit of implementing inhibitory or excitatory neuromodulation. Techniques such as sonogenetics, which activate acoustic-sensitive ion channels with ultrasound, leverage acoustic energy sources that may penetrate tissue at a greater depth, compared to light (Ibsen et al., 2015) .
Other viable technologies for bioelectronic medicine include focused ultrasound (FUS) alone, without genetic actuators. FUS has recently experienced a resurgence as a potential neuromodulatory modality due to its ability to deliver focused energy deep within the body. While FUS through bone requires long wavelengths, shorter wavelengths may be used to successfully increase the spatial resolution of peripheral nerve modulation. An additional advantage of FUS is the ability to either excite or inhibit nerves, depending on the energy levels used (Downs et al., 2018; Colucci et al., 2009) . The bioelectronic medicine field may also benefit from solutions that bypass the peripheral nerve and target the end organ itself. Recent results suggest that FUS targeting end organs such as the spleen can have similar effects as vagal nerve stimulation in reducing inflammatory signaling with fewer off-target effects (Cotero et al., 2019; Zachs et al., 2019) .
With regard to neural plasticity, the required spatial resolution of peripheral nerve stimulation in the context of facilitating learning is currently unknown. It may be possible that multiple neurophysiological mechanisms are responsible for the observed effects of peripheral nerve stimulation on learning. This will influence resolution requirements. For instance, if stimulation-induced improvements in learning are primarily a result of increased arousal via locus coeruleus activity and subsequent shifts in noradrenergic tone, spatial requirements for targeting the nerve may be low. On the other hand, it may be that specific stimulation of the peripheral nerve/fascicles can modulate perceptual and/or cognitive aspects of learning via more discrete and anatomically-diverse mechanisms. Importantly, spatial requirements for engaging a given peripheral nerve target may also be driven by the need to minimize off-target effects, such as the activation of nearby muscles and neighboring nerve branches. New technology development to understand the benefits of different approaches include invasive approaches that facilitate spatially selective peripheral nerve stimulation in animal models (e.g., Bong et al., 2019; Dingle et al., 2019) as well as minimally-invasive approaches, such as injectable polymer/metal electrodes that cure in the body (Trevathan et al., 2019) . Ultimately, the right spatial resolution should be facilitated by noninvasive or minimally invasive approaches to be considered for the non-medical applications of TNT.
In a similar manner, temporal resolution requirements for plasticity and learning may also depend on the specific approach and underlying neurophysiological mechanisms. For example, rodent studies have demonstrated that pairing vagus nerve stimulation (VNS) with an auditory response drives the reorganization of auditory cortex, and that the magnitude of the effect depends on stimulation parameters such as pulse rate, train duration, and current intensity Buell et al., 2018) . In another example, animal studies involving VNS paired with behavioral responses during motor task learning following stroke or spinal cord injury have suggested the importance of stimulating only on correct responses, and that efficacy is dependent upon the timing of stimulation (on the order of seconds) with respect to the behavioral response (Hays et al., 2014; Ganzer et al., 2018 ; see also Peng et al., 2019 for review) . Ongoing studies are investigating the effects of various peripheral nerve stimulation parameters on learning outcomes, and whether precise temporal pairing of stimulation with behavioral responses is important for facilitating neural plasticity and learning in healthy individuals.
Throughout the HAPTIX, ElectRx, and TNT portfolios, no single modality has yet demonstrated all of the characteristics necessary to satisfy the technical requirements for an idealized next-generation interface that could provide precise, axon-level resolution noninvasively. Future exploration may include a focus on integrating multiple modalities into a single interface technology. Multimodal interfaces may push the state-of-the-art by allowing technology developers to exploit the various physical tradeoffs of different techniques to advance the performance of neural interfaces.
Evaluation of efficacy
Evaluation of efficacy varies depending on the application. For example, the field of sensorized prosthetics relies heavily on functional metrics and user feedback. Bioelectronic medicine exploits a variety of nerve interfaces that are guided by biomarker-based measurements of disease state. Improving learning in healthy adults focuses on transcutaneous interfaces evaluated against current training times and behavioral performance. Here we discuss the methods that the programs use to evaluate system efficacy, along with future directions.
While the early safety and efficacy studies were performed in animal models (e.g., Ledbetter et al., 2013; Brill et al., 2018) , translating peripheral nerve technology to human amputees revolutionized somatosensory prosthetics due to the ability to collect verbal feedback from research participants about induced somatosensory percepts. To track the effects of peripheral stimulation on sensation, researchers use "perceptive field" maps that pictorially demonstrate where sensation is felt on the amputated limb. Research participants report not only the location of stimulation, but also the modality and quality. For instance, tactile percepts may include sensations of tingling, buzzing, vibration and graded pressure, while proprioceptive percepts may include reports of limb position as well as kinesthetic sensations of movement about joints (e.g. fingers curling). Perceptive field maps are largely idiosyncratic and must be generated for each individual research participant. Developers combine these maps with stimulation paradigms for providing useful sensory feedback, which vary from simple linear paradigms to model-based biomimetic approaches (e.g., Saal and Bensmaia, 2015) .
Beyond verbal reports of perceptions, user feedback is also important for quantifying the psychosocial benefit of sensation. To that end, HAPTIX researchers have used a series of questionnaires to understand the more elusive outcomes such as the sense of embodiment and quality of life (Graczyk et al., 2018; Page et al., 2018) . Of course, while user feedback is key, it is also important to demonstrate the usefulness of sensorimotor integration in an unbiased, quantitative manner. Current metrics have not kept pace with the rapid advancements in prosthetic limb technology and cannot evaluate improvements gained with sensation. To address this issue, HAPTIX researchers combined mathematical approaches, psychophysics, and theory to develop six novel metrics for quantifying the benefit of sensation. These metrics were validated in normative populations (nonamputees) as a benchmark (Blustein et al., 2018a; Thumser et al., 2018; Valevicius et al., 2018) . They demonstrate test-retest reliability, interrater reliability, and convergent validity in upper limb prosthetic users (e.g., Beckler et al., 2018; Marasco et al., 2018) . Each metric was designed to assess a specific aspect of sensorimotor integration, including speed/precision trade off , using Optimal Foraging Theory to shed light on prosthesis use efficiency and profitability (Beckler et al. 2019) , kinematic movement quality and visual attention demand Valevicius et al., 2019) incorporation of a prosthesis into oneself (Blustein et al., 2018b) , and the identification of the bottleneck in the prosthetic system (controller, sensory feedback, or internal model) (Shehata et al., 2018) . The next step for these researchers is to continue to socialize these metrics to help standardize their use in the field.
Similar to the field of prosthetics, assessing the efficacy of treatments for disease often relies on patient reporting as well as clinical outcomes and diagnoses. Toward the evaluation of efficacy, ElectRx teams are working to identify biomarkers that can provide real-time information about the disease state and its progression. Measures of these biological signals are intended to facilitate immediate feedback that would inform the amount, timing, and parameters of neuromodulation. Ideally, these biological signals would be sampled from the individual in a noninvasive manner such that near real-time or continuous monitoring would be possible to achieve the necessary Nyquist rate. Remaining challenges include identifying which markers are indicative of health status or other relevant measures, and understanding how these signals change over time in order to establish an appropriate sampling rate. Examples of biomarkers for evaluating treatment efficacy include fluid sampling to evaluate blood-borne cytokines or other inflammatory biomolecules, although researchers are pursing further in-depth analyses into the underlying signaling networks (Zachs et al., 2019; Koopman et al., 2016) . In another example, changes in electrical impedance across the membranes of the intestine effectively indicate the relative state of gut inflammation (Payne et al., 2018) . These signals can potentially be used as a non-molecular biomarker to modulate treatment of irritable bowel disease.
The ElectRx program also evaluates efficacy based on nerve target engagement. Efficacy of targeted nerve engagement is assessed with placement of electrodes on or around the targeted nerve to measure compound action potentials (e.g., Payne et al., 2019) . Verification of nerve engagement is also measured through indirect yet immediate physiological responses that vary depending on the target nerve. In the case of cervical vagus nerve, the Hering-Breuer reflex has long been observed to indicate nerve activation (Hering and Breuer, 1868) , although in programs such as ElectRx, more precise efficacy measures associated with organ function have been developed. In one case, the ElectRx program is using systemic glucose concentrations in response to noninvasive hepatic nerve stimulation with ultrasound (Coteral et al. 2019) to verify treatment efficacy. Notably, peripheral nerve modulation approaches such as optogenetics, sonogenetics, or FUS may not elicit end organ functional responses that can easily be measured by an implantable device to record nerve activity. In these cases, the use of physiological responses and reflexes, as well as alternative biomarker indications of engagement and efficacy, will be necessary.
Under TNT, program research is exploring behavioral outcomes of peripheral nerve stimulation as well as neural and physiological measures of nerve target engagement. Since the program goal is to ultimately improve learning, the gold standard metric in determining efficacy of a given set of stimulation parameters is behavioral performance on a skill or set of skills. Such measures may include improvements in accuracy, response times, or learning rates (e.g. shorter time to achieve a given level of proficiency). Depending on the difficulty of the skill, however, learning may occur on relatively long timescalesdays, weeks, or even months. Obtaining behavioral outcome measures across multiple sets of peripheral nerve stimulation parameters and at long timescales may result in unrealistic experimental time requirements for determining effective stimulation parameters. This time requirement becomes more of an issue when assessing generalization of stimulation approaches across multiple skills. One solution to this issue is to establish correlations across peripheral nerve stimulation parameter sets, neural activity, and behavioral outcomes using high throughput neurophysiological measures and relatively simple behavioral assays. Once initial optimal parameter sets have been established, they can then be tested and further refined using more complex behavioral measures.
Leveraging neural or physiological biomarkers of nerve target engagement may provide more immediatethough indirectmeasures of stimulation efficacy on improving task learning and/or performance. Such biomarkers may include real-time neural responses to task-related stimuli, structural and functional neural connectivity changes that occur during learning, or physiological measures, such as pupillary or cardiac responses. Effectively linking learning-related neurophysiological biomarkers to peripheral nerve stimulation parameters may also facilitate hypothesis-driven approaches to parameter optimization, negating the need for a more time-consuming exhaustive exploration of parameter space. While invasive approaches for biomarker assessment may be effective for initial peripheral nerve stimulation parameter optimization in animal models, noninvasive measures collected via brain imaging and/or wearable sensing devices (e.g., Bremner et al., 2019) may be more easily leveraged for refining stimulation parameters for human applications.
Finally, in addition to evaluating the efficacy of the systems and approaches, future work for all three programs involves improving the longevity of the elicited effect(s). This may include increasing the longevity of the interface itself (Judy, 2012) , but also means tailoring the stimulation parameters for long-term viability. For HAPTIX, this may mean developing decoders and encoders that do not need constant recalibration, and that are context-robust and generalizable. Stimulation algorithms must also be robust to the habituation and adaptation commonly experienced with respect to sensory modalities. For ElectRx, the required frequency of treatment will vary depending on the disease and the persistence of symptoms. The final system will need to be both versatile and robust in order to respond to the changing needs of the patient over time. Some symptoms may subside after a few treatments, while others may take weeks, months, or a lifetime to address (e.g., recurring episodes of PTSD). For TNT, the longevity of the effect of the technology is subject to unique considerations, depending on the type of learning and its associated mechanism(s). For example, improved performance that relies on nerve stimulation-induced arousal may be subject to the progressive loss of efficacy, as is commonly seen with other forms of arousal-promoting treatments (e.g., pharmacological stimulants). On the other hand, if improvements in learning are the result of increasing the neural response to a given sensory input, the benefits may take more time to become apparent during training, but may also remain more robust over time.
Ethical implications
Responsible technology development goes hand in hand with the consideration of relevant ethical implications. From program inception through completion, DARPA engages with independent experts in ethical, legal, and social implications (ELSI) to gain new perspectives on its technology developments. Though far from exhaustive, the following points are representative of the ethical topics and questions that are important to the HAPTIX, ElectRx, and TNT programs.
Enhancement
The question of enhancement is common to all three application spaces. For prosthetics, enhancement may mean a system that provides function beyond that of a typical personfor example, a wrist that rotates all the way around or electronics that produce novel modalities of sensory feedback. For bioelectronic medicine, it may mean increased immunity or resilience from injury. For neuromodulation to facilitate learning, where enhancement is not simply an important consideration, but rather the explicit goal, it means helping users improve the outcome of training. In conversations with ELSI advisors, DARPA has come to consider enhancement from the perspectives of risk tolerance, reversibility, personal agency, and accessibility.
First, neural interface system designers must assess acceptable levels of risk tolerance for interfaces in the context of individual applications of the technology. As previously described, greater risk may be tolerable for the restorative technologies being developed under the HAPTIX and ElectRx programs in the clinical domains, but could be less ethically justifiable for the performance benefits for healthy individuals sought by TNT. These considerations have influenced the shape of the respective interface systems; HAPTIX and ElectRx are developing a range of chronic and on-demand invasive and noninvasive interfaces, while TNT in humans focuses on noninvasive approaches for temporary use.
Second, one of DARPA's guiding principles is that any modifications be temporary in nature with reversible effects. The prosthetic systems being developed for HAPTIX and the bioelectronic interfaces being developed for ElectRx can be switched out, removed, reprogrammed, or turned off. In the case of TNT, the technology is intended for on-demand use during training to produce temporary effects on neural plasticity that last only for the duration of training. Whether the performance benefits are equivalent in longevity following traditional versus TNT-accelerated practice or diminish without subsequent stimulation-paired retraining is yet to be determined.
Third, all three PNS application spaces also require the developers to answer questions about personal agency and allocation of control over how the interfaces operate. For instance, how much control over an interface for restorative use should the clinician or developer have versus the user? Should the user simply have the ability to toggle an on/ off switch, be given the freedom to modify a wide host of parameters, or somewhere in between? For some interfaces, optimal performance may require the type of closed-loop, real-time system that only artificial intelligence can deliver. Such a system could adapt to changing conditions in the body and environment and automatically modify parameters without a human in the loop from moment to moment. What kind of design tradeoffs must be made to offer users meaningful input without diminishing the performance of the system?
Safety and security
Safety and security of the technology use are paramount to peripheral nerve interface development. In addition to using parameters that fall within safety limits, technology developers must be aware of the potential for off-target effects or unanticipated interactions, especially in the case of therapeutics and treatments to improve plasticity. As mentioned, future efforts to improve device resolution may minimize off-target stimulation and subsequently contribute to a more targeted system effect. Other safety concerns may include the unforeseen tradeoffs of system use. For example, in the case of plasticity, does improvement of a given skill result in an acquired deficiency in an associated process? Are there risks of long-term stimulation on nerve health? Does the approach result in dependencies due to habituation and adaptation? These questions merit further investigation.
Since many peripheral nerve interface systems rely on wireless communication, data security is a major consideration for device safety. Developers already make efforts to ensure the security of personal data transmission, and future designs will need to maintain strict security measures to protect the system from external manipulations. Appropriately securing data recorded by peripheral nerve interface systems may involve developing and/or integrating new modes of data transfer that are more robust to penetration. As these technologies exit the lab, it will also be important to establish the party responsible for maintaining the security of the device: the user, the manufacturer, the network administrator, or some combination thereof.
Additional considerations
As with all technology development, additional ethical concerns include the potential of a large divide between those who have access to the new technology and those who do not. While cost is less of a concern during the proof-of-concept phase, it is an important consideration as system manufacture begins to scale up for a wider demographic. Prosthetics and prescriptions will have the additional burden of securing reimbursement from insurance so that the technologies can be an option to anyone with medical coverage.
Other ethical considerations include topics specific to each application. For example, HAPTIX advances are accompanied by ongoing discussions about the effect of sensation on embodiment and sense of self (Page et al., 2018; Graczyk et al., 2019) . ElectRx technology includes regulatory and ethical questions surrounding the genetic modification of cells to make them sensitive to physical modalities such as light and sound (Gilbert et al., 2014) . For TNT, one consideration is the regulation of do-it-yourself (DIY) approaches. DIY neuroscience for improvements in learning has found a following in the realm of brain stimulation (Jwa, 2018; Fitz and Reiner, 2013; Wexler, 2017) , and the same questions of safety and proper use are applicable to the periphery as well. These types of ethical considerations, among a rich set of others, are important for scientists, engineers, ethicists, potential end users, and regulators to continue to discuss in tandem with technology development.
Since the agency is largely focused on initial technological proofs of concept, DARPA does not decisively answer all of these questions. However, by identifying and asking them it is shaping the development of the early generation of PNS interfaces. Future developers will need to pick up these threads and consider them anew in the context of regulatory review and commercial and medical applications.
Conclusions
DARPA has funded many interfaces for prosthetics, bioelectronic medicine, and plasticity. At the time of this writing, several funded teams have successfully initiated small human trials under local regulatory approvals as well as under U.S. Food and Drug Administration Investigational Device Exemptions. The next step is to transition these studies to larger clinical trials and potentially integrate them with a commercial market. While the programs discussed here have fueled the early high-risk phase of the research, commercial and government transition partners will further guide the developed technologies to long-term success. It may ultimately be up to transition partners, clinicians, and the patients themselves to help choose which specific technologies are successful.
Finally, while we discuss three distinct application spaces for peripheral interfaces here, other interesting use cases exist. For instance, peripheral interface technology may also be applicable to teleoperation, bidirectional control of immunity, direct neural networking between individuals, and beyond. As peripheral interface systems evolve, it will be important for regulation to accompany the trajectory of the technology and its uses.
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